A New Generation of Depression Treatment Approaches: Dr. Michael Thase

Emerging Therapies Could Address Unmet Needs In Patients | ..Dr. Thase reviewed data on some of those emerging medications, outlined the pathophysiology of depression, and discussed the limitations of available treatments at a session at Psych Congress 2018.

“There’s clearly not a sense that we’ve won, that we’ve got all that we need,” he said. “One out of 3 people who begin treatment don’t achieve, ultimately, the goal of having a full and sustained remission, and that’s an unacceptably high failure rate given all the ways that depression can complicate or potentially even ruin your life or lead to suicide.”

Dr. Thase believes that esketamine, a stereoisomer of ketamine which is administered intranasally, will likely be approved by the US Food and Drug Administration (FDA) in 2019. And he wouldn’t be surprised if, one day, ketamine programs can be found at most major treatment centers, as electroconvulsive therapy (ECT) and neuromodulation programs are…

Read Psych Congress article